CIK 0001869105 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
BridgeBio Oncology Therapeutics, Inc.
Sign in to watch- Ticker
- BBOT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857 702 0377
- Business address
- 256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Helix Acquisition Corp. II
- 4 Shares withheld for taxes Former Officer gave up 524 shares (to pay taxes)
- EFFECT Other Notice of Effectiveness
- POS AM Other Post-effective Amendment for Registration Statement
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 424B3 Offering Prospectus
- 8-K Event Executive or director change
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 424B3 Offering Prospectus
- 8-K Event Executive or director change · Regulation FD disclosure
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 424B3 Offering Prospectus
- 8-K Event Executive or director change
- 4 Grant or award Chief Financial Officer acquired 23,330 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 46,670 shares (grant or award)
- 4 Grant or award Chief Med & Dev Officer acquired 46,670 shares (grant or award)
- 424B3 Offering Prospectus
Page 3 of 10 · 187 filings